FDA slaps Hong Kong OTC drugmaker Nan San Pharma with warning letter

FDA Warning
FDA slaps Hong Kong OTC drugmaker Nan San Pharma with warning letter.

The FDA issued a warning letter to Hong Kong-based OTC drugmaker Nan San Pharmaceutical for failing to conduct appropriate laboratory testing and marketing misbranded products in the U.S.

An inspection of the company’s facility in Kwun Tong Kowloon, Hong Kong last September resulted in Nan San being placed on the regulatory agency’s import alert list in January.

In its warning letter, the FDA says inspectors found the company failed to perform microbial limit tests on batches of one of its products from 2013 to 2016. It found Nan San performed microbial limit testing on one batch in 2013 and used those results to release “subsequently-manufactured batches” to the U.S.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Additionally, the agency cited the company for setting expiration dates for some of its products without properly determining the stability characteristics of those products.

Musflex and Easy-Flex, two of Nan San’s OTC products, were found to be misbranded because their labels didn’t list active or inactive ingredients.

The FDA recently hit another Chinese OTC drugmaker, Zhejiang Ludao Technology, with a warning letter for data integrity and product testing issues.

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.